{"id":"W4409587015","doi":"10.1111/ene.70110","title":"The Results of <scp>ADVANCE</scp>‐<scp>CIDP IVIG</scp> Trial: Intravenous Immunoglobulin 10% Therapy With <scp>GAMMAGARD LIQUID</scp>/Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy","year":2025,"lang":"en","type":"article","venue":"European Journal of Neurology","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Takeda Development Center Americas","keywords":"Medicine; Polyradiculoneuropathy; Placebo; Internal medicine; Chronic inflammatory demyelinating polyneuropathy; Clinical endpoint; Multifocal motor neuropathy; Confidence interval; Randomized controlled trial; Antibody; Immunology; Guillain-Barre syndrome","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00361857,0.0007708024,0.001333205,0.0002166312,0.0002445413,0.0007433759,0.0005180793,0.0008958879,0.002732484],"category_scores_gemma":[0.002188031,0.000249233,0.001435102,0.0002312118,0.0004713388,0.0005873879,0.0002939482,0.001987757,0.0003698168],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006304868,"about_ca_system_score_gemma":0.0007758992,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005889477,"about_ca_topic_score_gemma":0.001682143,"domain_scores_codex":[0.9990061,0.0005615613,0.00006798802,0.0001357846,0.0001359409,0.00009266481],"domain_scores_gemma":[0.998257,0.0004503433,0.0005086889,0.0001619367,0.0002287835,0.0003931143],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9121683,0.006767035,0.006862891,0.001207003,0.002661018,0.0001653692,0.000111414,0.001664916,0.01204577,0.0003537383,0.008234794,0.04775775],"study_design_scores_gemma":[0.7272885,0.2005662,0.04991699,0.0003136949,0.003713846,0.0004644232,0.00006852169,0.001475222,0.005340625,0.0003248163,0.01046757,0.00005965248],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979157,0.008742757,0.0004810651,0.0009685383,0.0002881126,0.001677635,0.00361062,0.0000494425,0.005024856],"genre_scores_gemma":[0.9818349,0.002834416,0.001771802,0.001065939,0.0004922032,0.001010003,0.006898452,0.00003173664,0.004060576],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00361857,"threshold_uncertainty_score":0.01913702,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01288040415486335,"score_gpt":0.2555853554341349,"score_spread":0.2427049512792716,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}